Miami, FL, United States, December 2025 — eMed has announced the appointment of Taryn Timmons Erkelens as its new Chief People Officer, marking a pivotal move as the healthtech company scales its mission to transform population health with clinically guided GLP-1 access. With over a decade of experience leading people strategy, talent development, and organizational design, Taryn brings a robust blend of startup agility and enterprise insight to her new role.
Taryn most recently led People and Business Operations at Grayce, a family care benefits platform, where she played a dual role in driving internal growth and operational maturity. Her leadership across HR functions—spanning employee relations, internal communications, and executive coaching—was central to shaping culture during rapid expansion. In parallel, she continues to serve as Founder & Principal at Melon, advising high-growth startups on scalable team structures and compliant, human-centered people practices.
Previously, Taryn was Head of Portfolio People & Talent – US & Healthtech at Octopus Ventures, where she partnered with 30+ Seed to Series C startups across North America and Europe. Acting as an embedded People Partner, she guided companies through U.S. expansions, talent strategy, compensation frameworks, and DEI programs—building future-proof cultures from the ground up. Earlier in her career, she supported scale-ups at Cityblock Health, Addison Group, and Hilton, contributing to key organizational and workforce transformations.
As Chief People Officer, Taryn will lead eMed’s people strategy through its next phase of growth, aligning talent, leadership development, and culture with the company’s bold mission to responsibly address the global obesity epidemic through personalized, accessible GLP-1 treatments.
eMed is a U.S.-based healthtech company pioneering population-level access to GLP-1-based obesity treatment through its Empathetic AI™ platform. Serving employers, governments, unions, and NGOs, eMed delivers clinically backed, FDA-approved GLP-1 medications paired with structured, holistic programs that support long-term weight management. The company is deeply committed to clinical safety, beginning each patient journey with comprehensive blood testing and ongoing progress monitoring.
In a market fraught with inconsistent standards and unregulated products, eMed sets itself apart with an emphasis on responsible prescribing and evidence-based care. As the global burden of obesity escalates, eMed stands at the forefront of a scalable, ethical, and tech-enabled approach to preventive health.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
